Christine Voigt, PhD
Vice President of Clinical Sciences
Dr. Christine Voigt has more than 15 years of experience, holding varied roles throughout her career in research, regulatory affairs and clinical development. She received her BA from Wesleyan University (Molecular Biology and Biochemistry) and her PhD in Microbiology from Duke University.
Dr. Voigt joined CSL Behring 2010, and took the recombinant extended half-life Factor IX product, Idelvion®, from pre-IND to worldwide approval for patients with Hemophilia B. She then helped establish the transplant therapeutic area within clinical development for both solid organ transplant and hematopoietic transplant indications. She led 3 clinical development programs from concept to Phase 3 global clinical programs in 3 years, including regulatory strategy for the US, EU and Japan.
Prior to joining BlueSphere Bio, Dr. Voigt led regulatory and clinical strategy for early development programs as VP of Program Strategy and Execution at Gemini Therapeutics. In addition, she provided operational leadership and established processes within the company to execute on the overall program strategy.
